Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EVarQuit: Extended Pre-quit Varenicline
NCT03262662Phase 3Completed
- Sponsor
- University at Buffalo
- Start
- Oct 2017
- Primary completion
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of varenicline in Tobacco Use Disorder (TUD) (2 arms), sponsored by University at Buffalo. Primary endpoint: Continuous Abstinence at End-of-Treatment at 11 weeks. Started Oct 2017; status: completed.
02
Drugs
varenicline
03
Conditions
Tobacco Use Disorder (TUD)
Beyond the preview
Go deeper on NCT03262662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03262662.